What should I avoid while taking Valdecoxib 40mg tablets?

Avoid alcohol. Ingesting alcohol may increase the risk of gastrointestinal bleeding. Take with or without food. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Valdecoxib 40mg tablets?

Valdecoxib 40mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Valdecoxib 40mg tablets?

Valdecoxib 40mg tablets is the generic name. It is available under brand names including: Bextra 40mg tablets. (Source: NHS dm+d — Actual Medicinal Products)

Valdecoxib 40mg tablets

Tablet

40mg

Oral

Valdecoxib was removed from the Canadian, U.S., and E.U.

Active ingredients:

Valdecoxib

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 10.01.01

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC M01AH03

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Valdecoxib

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Valdecoxib

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(18 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Valdecoxib

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Valdecoxib

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 productsShow details

1 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Valdecoxib on the MHRA register

Bextra 40mg tablets

Pfizer Ltd

Discontinued

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Daily doseShow details

WHO defined daily dose (DDD)

10 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Celecoxib 120mg/4.8ml oral solution unit dose bottles sugar free

Oral solution

120mg/4.8ml

Same therapeutic group

Celecoxib 50mg/5ml oral suspension

Oral suspension

50mg/5ml

Same therapeutic group

Celecoxib 400mg capsules

Capsule

400mg

Same therapeutic group

Etoricoxib 30mg tablets

Tablet

30mg

Same therapeutic group

Lumiracoxib 100mg tablets

Tablet

100mg

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Valdecoxib

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Valdecoxib

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42112611000001100

dm+d ID

42112611000001100

VTM (Virtual Therapeutic Moiety)

777908009

VMP (Virtual Medicinal Product)

42112611000001100

BNF code

10010100

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

M01AH03

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

158 found

Half-life

8-11 hours

Mechanism

Both COX-1 and COX-2 catalyze the conversion of arachidonic acid to prostaglandi…

Food interactions

2 warnings

Human targets

3 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

83%

Oral bioavailability is 83%.

Half-life

8-11 hours

8-11 hours

Protein binding

98%

Volume of distribution

86 L

* 86 L

Metabolism

Hepatic (involves CYP3A4 and 2C9)

Elimination

Valdecoxib is eliminated predominantly via hepatic metabolism with less than 5% of the dose excreted unchanged in the urine and feces.…

Clearance

6 L/h

* oral cl=6 L/h
* 6 – 7 L/h [In patients undergoing hemodialysis]
* 6 – 7 L/h [healthy elderly subjects]

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Withdrawn

Small molecule

About this compound

Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.

Properties:

solid

Avg. mass: 314.36 Da

View FDA drug label

DrugBank indication

For the treatment of osteoarthritis and dysmenorrhoea

Also known as(61)

Valdecoxib

1.14.99.1

COX-2

COX2

Cyclooxygenase-2

PGH synthase 2

PGHS-2

PHS II

Dosage forms(9)

Tablet, film coated (Oral)

Tablet, film coated (Oral) — 10 mg/1

Tablet, film coated (Oral) — 20 mg/1

Tablet, coated (Oral) — 40 mg

Tablet, film coated (Oral) — 10 mg

Tablet, coated (Oral) — 20 mg

Tablet (Oral) — 20 mg

Tablet (Oral) — 40 mg

Molecular properties(19)

Drug interactions(1690)

Known interactions with other medications. Always consult a healthcare professional.

Amlodipine

Moderate

DB00381

The metabolism of Valdecoxib can be decreased when combined with Amlodipine.

Check this interaction

Midodrine

Unknown severity

DB00211

The risk or severity of hypertension can be increased when Midodrine is combined with Valdecoxib.

Check this interaction

Isoetharine

Unknown severity

DB00221

The risk or severity of hypertension can be increased when Isoetharine is combined with Valdecoxib.

Check this interaction

Zolmitriptan

Unknown severity

DB00315

The risk or severity of hypertension can be increased when Zolmitriptan is combined with Valdecoxib.

Check this interaction

Norepinephrine

Unknown severity

DB00368

The risk or severity of hypertension can be increased when Norepinephrine is combined with Valdecoxib.

Check this interaction

Phenylephrine

Unknown severity

DB00388

The risk or severity of hypertension can be increased when Phenylephrine is combined with Valdecoxib.

Check this interaction

Phenylpropanolamine

Unknown severity

DB00397

The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with Valdecoxib.

Check this interaction

Droperidol

Unknown severity

DB00450

The risk or severity of hypertension can be increased when Droperidol is combined with Valdecoxib.

Check this interaction

Doxapram

Unknown severity

DB00561

The risk or severity of hypertension can be increased when Doxapram is combined with Valdecoxib.

Check this interaction

Atropine

Unknown severity

DB00572

The risk or severity of hypertension can be increased when Atropine is combined with Valdecoxib.

Check this interaction

Linezolid

Unknown severity

DB00601

The risk or severity of hypertension can be increased when Valdecoxib is combined with Linezolid.

Check this interaction

Metaraminol

Unknown severity

DB00610

The risk or severity of hypertension can be increased when Valdecoxib is combined with Metaraminol.

Check this interaction

Furazolidone

Unknown severity

DB00614

The risk or severity of hypertension can be increased when Valdecoxib is combined with Furazolidone.

Check this interaction

Thioridazine

Unknown severity

DB00679

The risk or severity of hypertension can be increased when Valdecoxib is combined with Thioridazine.

Check this interaction

Nicergoline

Unknown severity

DB00699

The risk or severity of hypertension can be increased when Valdecoxib is combined with Nicergoline.

Check this interaction

Methoxamine

Unknown severity

DB00723

The risk or severity of hypertension can be increased when Valdecoxib is combined with Methoxamine.

Check this interaction

Isoflurane

Unknown severity

DB00753

The risk or severity of hypertension can be increased when Valdecoxib is combined with Isoflurane.

Check this interaction

Propiomazine

Unknown severity

DB00777

The risk or severity of hypertension can be increased when Valdecoxib is combined with Propiomazine.

Check this interaction

Minaprine

Unknown severity

DB00805

The risk or severity of hypertension can be increased when Valdecoxib is combined with Minaprine.

Check this interaction

Orciprenaline

Unknown severity

DB00816

The risk or severity of hypertension can be increased when Valdecoxib is combined with Orciprenaline.

Check this interaction

Phenmetrazine

Unknown severity

DB00830

The risk or severity of hypertension can be increased when Valdecoxib is combined with Phenmetrazine.

Check this interaction

Trifluoperazine

Unknown severity

DB00831

The risk or severity of hypertension can be increased when Valdecoxib is combined with Trifluoperazine.

Check this interaction

Pseudoephedrine

Unknown severity

DB00852

The risk or severity of hypertension can be increased when Valdecoxib is combined with Pseudoephedrine.

Check this interaction

Ritodrine

Unknown severity

DB00867

The risk or severity of hypertension can be increased when Valdecoxib is combined with Ritodrine.

Check this interaction

Flupentixol

Unknown severity

DB00875

The risk or severity of hypertension can be increased when Valdecoxib is combined with Flupentixol.

Check this interaction

Remifentanil

Unknown severity

DB00899

The risk or severity of hypertension can be increased when Valdecoxib is combined with Remifentanil.

Check this interaction

Bitolterol

Unknown severity

DB00901

The risk or severity of hypertension can be increased when Valdecoxib is combined with Bitolterol.

Check this interaction

Oxymetazoline

Unknown severity

DB00935

The risk or severity of hypertension can be increased when Valdecoxib is combined with Oxymetazoline.

Check this interaction

Diethylpropion

Unknown severity

DB00937

The risk or severity of hypertension can be increased when Valdecoxib is combined with Diethylpropion.

Check this interaction

Naratriptan

Unknown severity

DB00952

The risk or severity of hypertension can be increased when Valdecoxib is combined with Naratriptan.

Check this interaction

Frovatriptan

Unknown severity

DB00998

The risk or severity of hypertension can be increased when Valdecoxib is combined with Frovatriptan.

Check this interaction

Isoprenaline

Unknown severity

DB01064

The risk or severity of hypertension can be increased when Valdecoxib is combined with Isoprenaline.

Check this interaction

Arbutamine

Unknown severity

DB01102

The risk or severity of hypertension can be increased when Valdecoxib is combined with Arbutamine.

Check this interaction

Desflurane

Unknown severity

DB01189

The risk or severity of hypertension can be increased when Valdecoxib is combined with Desflurane.

Check this interaction

Isocarboxazid

Unknown severity

DB01247

The risk or severity of hypertension can be increased when Valdecoxib is combined with Isocarboxazid.

Check this interaction

Lisdexamfetamine

Unknown severity

DB01255

The risk or severity of hypertension can be increased when Valdecoxib is combined with Lisdexamfetamine.

Check this interaction

Fenoterol

Unknown severity

DB01288

The risk or severity of hypertension can be increased when Valdecoxib is combined with Fenoterol.

Check this interaction

Pirbuterol

Unknown severity

DB01291

The risk or severity of hypertension can be increased when Valdecoxib is combined with Pirbuterol.

Check this interaction

Ephedra sinica root

Unknown severity

DB01363

The risk or severity of hypertension can be increased when Valdecoxib is combined with Ephedra sinica root.

Check this interaction

Ephedrine

Unknown severity

DB01364

The risk or severity of hypertension can be increased when Valdecoxib is combined with Ephedrine.

Check this interaction

Mephentermine

Unknown severity

DB01365

The risk or severity of hypertension can be increased when Valdecoxib is combined with Mephentermine.

Check this interaction

Procaterol

Unknown severity

DB01366

The risk or severity of hypertension can be increased when Valdecoxib is combined with Procaterol.

Check this interaction

Methotrimeprazine

Unknown severity

DB01403

The risk or severity of hypertension can be increased when Valdecoxib is combined with Methotrimeprazine.

Check this interaction

Clenbuterol

Unknown severity

DB01407

The risk or severity of hypertension can be increased when Valdecoxib is combined with Clenbuterol.

Check this interaction

Bambuterol

Unknown severity

DB01408

The risk or severity of hypertension can be increased when Valdecoxib is combined with Bambuterol.

Check this interaction

MMDA

Unknown severity

DB01442

The risk or severity of hypertension can be increased when Valdecoxib is combined with MMDA.

Check this interaction

Midomafetamine

Unknown severity

DB01454

The risk or severity of hypertension can be increased when Valdecoxib is combined with Midomafetamine.

Check this interaction

2,5-Dimethoxy-4-ethylamphetamine

Unknown severity

DB01467

The risk or severity of hypertension can be increased when Valdecoxib is combined with 2,5-Dimethoxy-4-ethylamphetamine.

Check this interaction

4-Methoxyamphetamine

Unknown severity

DB01472

The risk or severity of hypertension can be increased when Valdecoxib is combined with 4-Methoxyamphetamine.

Check this interaction

Brolamfetamine

Unknown severity

DB01484

The risk or severity of hypertension can be increased when Valdecoxib is combined with 4-Bromo-2,5-dimethoxyamphetamine.

Check this interaction

Showing 50 of 1690 interactions

Food & lifestyle interactions

Avoid Alcohol

Avoid alcohol. Ingesting alcohol may increase the risk of gastrointestinal bleeding.

Advice

Take with or without food.

Toxicity & overdose

Symptoms following acute NSAID overdoses are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression and coma may occur, but are rare.

How it works

Mechanism of action

Both COX-1 and COX-2 catalyze the conversion of arachidonic acid to prostaglandin (PG) H2, the precursor of PGs and thromboxane. Valdecoxib selectively inhibits the cyclooxygenase-2 (COX-2) enzyme, important for the mediation of inflammation and pain. Unlike non-selective NSAIDs, valdecoxib does not inhibit platelet aggregation.

Pharmacodynamics

Valdecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is classified as a nonsteroidal anti-inflammatory drug (NSAID). Valdecoxib is used for its anti-inflammatory, analgesic, and antipyretic activities in the management of osteoarthritis (OA) and for the treatment of dysmenorrhea or acute pain. Unlike celecoxib, valdecoxib lacks a sulfonamide chain and does not require CYP450 enzymes for metabolism.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Oral bioavailability is 83%.

Half-life

8-11 hours

Protein binding

98%

Volume of distribution

* 86 L

Metabolism

Hepatic (involves CYP3A4 and 2C9)

Route of elimination

Valdecoxib is eliminated predominantly via hepatic metabolism with less than 5% of the dose excreted unchanged in the urine and feces. About 70% of the dose is excreted in the urine as metabolites, and about 20% as valdecoxib N-glucuronide.

Clearance

* oral cl=6 L/h
* 6 – 7 L/h [In patients undergoing hemodialysis]
* 6 – 7 L/h [healthy elderly subjects]

Drug targets(3)

Proteins and enzymes this drug interacts with in the body

Prostaglandin G/H synthase 2

BE0000262

PTGS2

inhibitor

Specific functionenzyme binding

Cellular location

Microsome membrane

General function & pharmacology

Dual cyclooxygenase and peroxidase in the biosynthesis pathway of prostanoids, a class of C20 oxylipins mainly derived from arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate, AA, C20:4(n-6)), with a particular role in the inflammatory response .
PMID:11939906 PMID:16373578 PMID:19540099 PMID:22942274 PMID:26859324 PMID:27226593 PMID:7592599 PMID:7947975 PMID:9261177

The cyclooxygenase activity oxygenates AA to the hydroperoxy endoperoxide prostaglandin G2 (PGG2), and the peroxidase activity reduces PGG2 to the hydroxy endoperoxide prostaglandin H2 (PGH2), the precursor of all 2-series prostaglandins and thromboxanes .
PMID:16373578 PMID:22942274 PMID:26859324 PMID:27226593 PMID:7592599 PMID:7947975 PMID:9261177

This complex transformation is initiated by abstraction of hydrogen at carbon 13 (with S-stereochemistry), followed by insertion of molecular O2 to form the endoperoxide bridge between carbon 9 and 11 that defines prostaglandins. The insertion of a second molecule of O2 (bis-oxygenase activity) yields a hydroperoxy group in PGG2 that is then reduced to PGH2 by two electrons .
PMID:16373578 PMID:22942274 PMID:26859324 PMID:27226593 PMID:7592599 PMID:7947975 PMID:9261177

Similarly catalyzes successive cyclooxygenation and peroxidation of dihomo-gamma-linoleate (DGLA, C20:3(n-6)) and eicosapentaenoate (EPA, C20:5(n-3)) to corresponding PGH1 and PGH3, the precursors of 1- and 3-series prostaglandins .
PMID:11939906 PMID:19540099
In an alternative pathway of prostanoid biosynthesis, converts 2-arachidonoyl lysophopholipids to prostanoid lysophopholipids, which are then hydrolyzed by intracellular phospholipases to release free prostanoids .
PMID:27642067
Metabolizes 2-arachidonoyl glycerol yielding the glyceryl ester of PGH2, a process that can contribute to pain response .
PMID:22942274
Generates lipid mediators from n-3 and n-6 polyunsaturated fatty acids (PUFAs) via a lipoxygenase-type mechanism. Oxygenates PUFAs to hydroperoxy compounds and then reduces them to corresponding alcohols .
PMID:11034610 PMID:11192938 PMID:9048568 PMID:9261177

Plays a role in the generation of resolution phase interaction products (resolvins) during both sterile and infectious inflammation .
PMID:12391014
Metabolizes docosahexaenoate (DHA, C22:6(n-3)) to 17R-HDHA, a precursor of the D-series resolvins (RvDs) .
PMID:12391014
As a component of the biosynthetic pathway of E-series resolvins (RvEs), converts eicosapentaenoate (EPA, C20:5(n-3)) primarily to 18S-HEPE that is further metabolized by ALOX5 and LTA4H to generate 18S-RvE1 and 18S-RvE2 .
PMID:21206090
In vascular endothelial cells, converts docosapentaenoate (DPA, C22:5(n-3)) to 13R-HDPA, a precursor for 13-series resolvins (RvTs) shown to activate macrophage phagocytosis during bacterial infection .
PMID:26236990
In activated leukocytes, contributes to oxygenation of hydroxyeicosatetraenoates (HETE) to diHETES (5,15-diHETE and 5,11-diHETE) .
PMID:22068350 PMID:26282205
Can also use linoleate (LA, (9Z,12Z)-octadecadienoate, C18:2(n-6)) as substrate and produce hydroxyoctadecadienoates (HODEs) in a regio- and stereospecific manner, being (9R)-HODE ((9R)-hydroxy-(10E,12Z)-octadecadienoate) and (13S)-HODE ((13S)-hydroxy-(9Z,11E)-octadecadienoate) its major products (By similarity).

During neuroinflammation, plays a role in neuronal secretion of specialized preresolving mediators (SPMs) 15R-lipoxin A4 that regulates phagocytic microglia (By similarity)

Carbonic anhydrase 2

BE0000322

CA2

inhibitor

Specific functionarylesterase activity

Cellular location

Cytoplasm

General function & pharmacology

Catalyzes the reversible hydration of carbon dioxide .
PMID:11327835 PMID:11802772 PMID:11831900 PMID:12056894 PMID:12171926 PMID:1336460 PMID:14736236 PMID:15300855 PMID:15453828 PMID:15667203 PMID:15865431 PMID:16106378 PMID:16214338 PMID:16290146 PMID:16686544 PMID:16759856 PMID:16807956 PMID:17127057 PMID:17251017 PMID:17314045 PMID:17330962 PMID:17346964 PMID:17540563 PMID:17588751 PMID:17705204 PMID:18024029 PMID:18162396 PMID:18266323 PMID:18374572 PMID:18481843 PMID:18618712 PMID:18640037 PMID:18942852 PMID:1909891 PMID:1910042 PMID:19170619 PMID:19186056 PMID:19206230 PMID:19520834 PMID:19778001 PMID:7761440 PMID:7901850 PMID:8218160 PMID:8262987 PMID:8399159 PMID:8451242 PMID:8485129 PMID:8639494 PMID:9265618 PMID:9398308

Can also hydrate cyanamide to urea .
PMID:10550681 PMID:11015219
Stimulates the chloride-bicarbonate exchange activity of SLC26A6 .
PMID:15990874
Essential for bone resorption and osteoclast differentiation .
PMID:15300855
Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption

Carbonic anhydrase 3

BE0003625

CA3

inhibitor

Specific functioncarbonate dehydratase activity

Cellular location

Cytoplasm

General function & pharmacology

Reversible hydration of carbon dioxide

Metabolizing enzymes(3)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

UGT1A9UDP-glucuronosyltransferase 1A9

substrate

CYP2C9Cytochrome P450 2C9

substrate

inhibitor

CYP3A4Cytochrome P450 3A4

substrate

Biological pathways(1)

Valdecoxib Action Pathway

Involved compounds

Prostaglandin D2,Arachidonic Acid,Calcium,Dinoprostone,Glutathione,Glutamic acid,Magnesium cation,Mesoheme,Prostaglandin G2,Valdecoxib,Zinc

ATC classification(2 codes)

ATC M01AH03

ATC G01AE10

Affected organisms(1)

Humans and other mammals

Experimental properties(1)

External resources(2)

RxList Drugs.com

Protein Data Bank entries(1)

2aw1

Commercial products(4)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Valdecoxib

DB00580

CAS number

181695-72-7

UNII (FDA)

2919279Q3W

InChI Key (molecular fingerprint)

LNPDTQAFDNKSHK-UHFFFAOYSA-N

Additional database identifiers

ChEBI

63634

PubChem Compound

119607

PubChem Substance

46506229

ChemSpider

106796

BindingDB

13063

PharmGKB

PA10226

PDB

COX

Therapeutic Targets Database

DAP001541

Wikipedia

Valdecoxib

ChEMBL

CHEMBL865

ZINC

ZINC000000006694

RxCUI

278567

HUGO Gene Nomenclature Committee (HGNC)

HGNC:9605

GenAtlas

PTGS2

GeneCards

PTGS2

GenBank Gene Database

L15326

GenBank Protein Database

291988

Guide to Pharmacology

1376

UniProtKB

P35354

UniProt Accession

PGH2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1373

GenAtlas

CA2

GeneCards

CA2

GenBank Gene Database

M77181

GenBank Protein Database

179780

Guide to Pharmacology

3092

UniProtKB

P00918

UniProt Accession

CAH2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1374

GeneCards

CA3

GenBank Gene Database

AK313254

GenBank Protein Database

189053812

UniProtKB

P07451

UniProt Accession

CAH3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12541

GeneCards

UGT1A9

GenBank Gene Database

S55985

GenBank Protein Database

7690346

UniProtKB

O60656

UniProt Accession

UD19_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2623

GenAtlas

CYP2C9

GeneCards

CYP2C9

GenBank Gene Database

AY341248

Guide to Pharmacology

1326

UniProtKB

P11712

UniProt Accession

CP2C9_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

Patent information

All patents expired, 3 expired

7135489

United States

Approved 14 Nov 2006 · Expires 12 Aug 2017

Expired

2212836

Canada

Approved 12 Aug 2003 · Expires 12 Feb 2016

Expired

5633272

United States

Approved 27 May 1997 · Expires 13 Feb 2015

Expired

Patent protection has expired — generic versions may be available.

Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated about 1 month ago(4 Mar 2026)

Back to medicines

Valdecoxib 40mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science
7

Chemical identifiers

Valdecoxib

Additional database identifiers

Patent information

DrugBank citations

Valdecoxib 40mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science7

Chemical identifiers

Valdecoxib

Additional database identifiers

Patent information

DrugBank citations

Deep science
7